Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Metabolites ; 13(7)2023 Jun 21.
Article in English | MEDLINE | ID: mdl-37512481

ABSTRACT

Past chemopreventive human trials on dietary selenium supplements produced controversial outcomes. They largely employed selenomethionine (SeM)-based diets. SeM was less toxic than selenite or methylseleninic acid (MSeA) to lung cancer cells. We thus investigated the toxic action of these Se agents in two non-small cell lung cancer (NSCLC) cell lines and ex vivo organotypic cultures (OTC) of NSCLC patient lung tissues. Stable isotope-resolved metabolomics (SIRM) using 13C6-glucose and 13C5,15N2-glutamine tracers with gene knockdowns were employed to examine metabolic dysregulations associated with cell type- and treatment-dependent phenotypic changes. Inhibition of key anaplerotic processes, pyruvate carboxylation (PyC) and glutaminolysis were elicited by exposure to MSeA and selenite but not by SeM. They were accompanied by distinct anabolic dysregulation and reflected cell type-dependent changes in proliferation/death/cell cycle arrest. NSCLC OTC showed similar responses of PyC and/or glutaminolysis to the three agents, which correlated with tissue damages. Altogether, we found differential perturbations in anaplerosis-fueled anabolic pathways to underlie the distinct anti-cancer actions of the three Se agents, which could also explain the failure of SeM-based chemoprevention trials.

2.
Sci Immunol ; 7(70): eabm8161, 2022 04 29.
Article in English | MEDLINE | ID: mdl-35486677

ABSTRACT

Effective T cell-mediated immune responses require the proper allocation of metabolic resources to sustain growth, proliferation, and cytokine production. Epigenetic control of the genome also governs T cell transcriptome and T cell lineage commitment and maintenance. Cellular metabolic programs interact with epigenetic regulation by providing substrates for covalent modifications of chromatin. By using complementary genetic, epigenetic, and metabolic approaches, we revealed that tricarboxylic acid (TCA) cycle flux fueled biosynthetic processes while controlling the ratio of succinate/α-ketoglutarate (α-KG) to modulate the activities of dioxygenases that are critical for driving T cell inflammation. In contrast to cancer cells, where succinate dehydrogenase (SDH)/complex II inactivation drives cell transformation and growth, SDH/complex II deficiency in T cells caused proliferation and survival defects when the TCA cycle was truncated, blocking carbon flux to support nucleoside biosynthesis. Replenishing the intracellular nucleoside pool partially relieved the dependence of T cells on SDH/complex II for proliferation and survival. SDH deficiency induced a proinflammatory gene signature in T cells and promoted T helper 1 and T helper 17 lineage differentiation. An increasing succinate/α-KG ratio in SDH-deficient T cells promoted inflammation by changing the pattern of the transcriptional and chromatin accessibility signatures and consequentially increasing the expression of the transcription factor, PR domain zinc finger protein 1. Collectively, our studies revealed a role of SDH/complex II in allocating carbon resources for anabolic processes and epigenetic regulation in T cell proliferation and inflammation.


Subject(s)
Epigenesis, Genetic , Succinate Dehydrogenase , Cell Proliferation , Chromatin , Electron Transport Complex II/deficiency , Humans , Inflammation/genetics , Ketoglutaric Acids/chemistry , Ketoglutaric Acids/metabolism , Ketoglutaric Acids/pharmacology , Metabolism, Inborn Errors , Mitochondrial Diseases , Nucleosides , Succinate Dehydrogenase/genetics , Succinate Dehydrogenase/metabolism , Succinates
3.
Proteomics ; 19(21-22): e1800486, 2019 11.
Article in English | MEDLINE | ID: mdl-31298457

ABSTRACT

Large clinical trials and model systems studies suggest that the chemical form of selenium dictates chemopreventive and chemotherapeutic efficacy. Selenite induces excess ROS production, which mediates autophagy and eventual cell death in non-small cell lung cancer adenocarcinoma A549 cells. As the mechanisms underlying these phenotypic effects are unclear, the clinical relevance of selenite for cancer therapy remains to be determined. The authors' previous stable isotope-resolved metabolomics and gene expression analysis showed that selenite disrupts glycolysis, the Krebs cycle, and polyamine metabolism in A549 cells, potentially through perturbed glutaminolysis, a vital anaplerotic process for proliferation of many cancer cells. Herein, the role of the glutaminolytic enzyme glutaminase 1 (GLS1) in selenite's toxicity in A549 cells and in patient-derived lung cancer tissues is investigated. Using [13 C6 ]-glucose and [13 C5 ,15 N2 ]-glutamine tracers, selenite's action on metabolic networks is determined. Selenite inhibits glutaminolysis and glutathione synthesis by suppressing GLS1 expression, and blocks the Krebs cycle, but transiently activates pyruvate carboxylase activity. Glutamate supplementation partially rescues these anti-proliferative and oxidative stress activities. Similar metabolic perturbations and necrosis are observed in selenite-treated human patients' cancerous lung tissues ex vivo. The results support the hypothesis that GLS1 suppression mediates part of the anti-cancer activity of selenite both in vitro and ex vivo.


Subject(s)
Glutaminase/genetics , Lung Neoplasms/drug therapy , Metabolomics , Selenious Acid/pharmacology , A549 Cells , Antineoplastic Agents/pharmacology , Autophagy/drug effects , Cell Proliferation/drug effects , Citric Acid Cycle/drug effects , Female , Gene Expression Regulation, Neoplastic/drug effects , Glucose/metabolism , Glutamic Acid/genetics , Glutamic Acid/metabolism , Humans , Lung Neoplasms/genetics , Lung Neoplasms/pathology , Male , Metabolic Networks and Pathways/genetics , Oxidative Stress/drug effects , Reactive Oxygen Species/metabolism
4.
J Biol Chem ; 292(28): 11601-11609, 2017 07 14.
Article in English | MEDLINE | ID: mdl-28592486

ABSTRACT

Metabolic reprogramming is a hallmark of cancer. The changes in metabolism are adaptive to permit proliferation, survival, and eventually metastasis in a harsh environment. Stable isotope-resolved metabolomics (SIRM) is an approach that uses advanced approaches of NMR and mass spectrometry to analyze the fate of individual atoms from stable isotope-enriched precursors to products to deduce metabolic pathways and networks. The approach can be applied to a wide range of biological systems, including human subjects. This review focuses on the applications of SIRM to cancer metabolism and its use in understanding drug actions.


Subject(s)
Energy Metabolism , Metabolomics/methods , Neoplasms/metabolism , Animals , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Carbon Isotopes , Cellular Reprogramming/drug effects , Drug Evaluation, Preclinical/methods , Drug Evaluation, Preclinical/trends , Energy Metabolism/drug effects , Fourier Analysis , Humans , Magnetic Resonance Spectroscopy , Mass Spectrometry , Metabolomics/trends , Neoplasms/drug therapy , Neoplasms/enzymology , Nitrogen Isotopes
5.
Anal Chim Acta ; 651(2): 201-8, 2009 Oct 05.
Article in English | MEDLINE | ID: mdl-19782812

ABSTRACT

We have coupled 2D-NMR and infusion FT-ICR-MS with computer-assisted assignment to profile 13C-isotopologues of glycerophospholipids (GPL) directly in crude cell extracts, resulting in very high information throughput of >3000 isobaric molecules in a few minutes. A mass accuracy of better than 1 ppm combined with a resolution of 100,000 at the measured m/z was required to distinguish isotopomers from other GPL structures. Isotopologue analysis of GPLs extracted from LCC2 breast cancer cells grown on [U-13C]-glucose provided a rich trove of information about the biosynthesis and turnover of the GPLs. The isotopologue intensity ratios from the FT-ICR-MS were accurate to approximately 1% or better based on natural abundance background, and depended on the signal-to-nose ratio. The time course of incorporation of 13C from [U-13C]-glucose into a particular phosphatidylcholine was analyzed in detail, to provide a quantitative measure of the sizes of glycerol, acetyl CoA and total GPL pools in growing LCC2 cells. Independent and complementary analysis of the positional 13C enrichment in the glycerol and fatty acyl chains obtained from high resolution 2D NMR was used to verify key aspects of the model. This technology enables simple and rapid sample preparation, has rapid analysis, and is generally applicable to unfractionated GPLs of almost any head group, and to mixtures of other classes of metabolites.


Subject(s)
Magnetic Resonance Spectroscopy/methods , Phosphatidylcholines/biosynthesis , Spectrometry, Mass, Electrospray Ionization/methods , Carbon Isotopes/metabolism , Cell Line, Tumor , Glucose/metabolism , Humans , Isotope Labeling , Phosphatidylcholines/analysis
6.
Drug Metab Rev ; 38(4): 707-32, 2006.
Article in English | MEDLINE | ID: mdl-17145697

ABSTRACT

Transcriptomics provides the tool for deciphering gene expression networks, and proteomics links these networks to protein products. The third crucial partner is metabolomics, which defines the metabolic network(s) linked to gene expression. NMR and mass spectrometry enable the broad screen analysis of the metabolome and its transformation pathways, transcending classical targeted metabolic studies. These tools were combined to investigate the anticancer mechanisms of different selenium forms in human lung cancer cells. Using 2-D NMR and tandem-MS, we mapped perturbations of 13C labeling patterns in numerous metabolites induced by selenite and selenomethionine. This information was used to interpret selenite-induced changes in gene expression networks. Linking metabolic dysfunctions to altered gene expression profiles provided new insights into the regulatory network underlying the metabolic dysfunctions, enabled the assembly of discrete gene expression events into functional pathways, and revealed protein targets for proteomic analysis.


Subject(s)
Anticarcinogenic Agents/metabolism , Anticarcinogenic Agents/pharmacology , Selenium/metabolism , Selenium/pharmacology , Transcription, Genetic/genetics , Animals , Gene Expression Regulation, Neoplastic/drug effects , Gene Expression Regulation, Neoplastic/physiology , Humans , Magnetic Resonance Spectroscopy , Mass Spectrometry , Neoplasms/metabolism , Proteomics , Transcription, Genetic/drug effects , Transcription, Genetic/physiology
SELECTION OF CITATIONS
SEARCH DETAIL